VistaGen Therapeutics Q3 EPS $(0.22) Beats $(0.30) Estimate, Sales $411.40K Miss $544.50K Estimate
Portfolio Pulse from Benzinga Newsdesk
VistaGen Therapeutics (NASDAQ:VTGN) reported Q3 earnings with a per-share loss of $(0.22), surpassing the $(0.30) estimate, marking an 84.51% improvement year-over-year. However, their sales of $411.40K fell short of the $544.50K estimate, despite a 129.06% increase from the previous year.
February 13, 2024 | 9:31 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
VistaGen Therapeutics reported better-than-expected Q3 EPS but missed sales estimates, showing significant year-over-year growth in both metrics.
The mixed results with an EPS beat but a miss on sales forecasts could lead to a neutral short-term impact on VTGN's stock price. The significant improvement in year-over-year performance might be seen positively, but the sales miss could temper investor enthusiasm.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100